Welcome to our dedicated page for LMNGF news (Ticker: LMNGF), a resource for investors and traders seeking the latest updates and insights on LMNGF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMNGF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMNGF's position in the market.
BioVaxys Technology Corp. announced a collaboration with BioElpida to develop GMP-grade bioproduction for its ovarian cancer vaccine BXV-0918A. The partnership aims for clinical-grade manufacturing, with a Phase I/II trial expected in early 2022, pending EMEA approval. Over 300,000 women are diagnosed with ovarian cancer annually, highlighting the urgent market need. The global ovarian cancer drugs market, valued at US$1.2B in 2017, is projected to reach US$4.6B by 2026, indicating a growing opportunity for BioVaxys.
BioVaxys Technology Corp. (OTC: LMNGF) has achieved DTCC full service eligibility in the US, allowing its shares to be held and traded through DTC's electronic system. This development enhances the liquidity of BioVaxys shares, which will benefit investors by facilitating easier trading. The company is focused on developing vaccines and immuno-diagnostics for viral and oncology applications, including a SARS-CoV-2 vaccine and cancer therapies. The press release highlights BioVaxys' commitment to advancing its clinical trials and protecting its intellectual property.
BioVaxys Technology Corp. (OTC: LMNGF) and Procare Health Iberia have formed a collaboration for the co-development and commercialization of BioVaxys vaccines targeting ovarian cancer, cervical cancer, and HPV. The partnership will initiate a Phase I clinical study of BVX-0918A in Spain, with BioVaxys managing vaccine production and technology, while Procare Health will handle clinical and marketing aspects. Both companies will share costs for the study, and Procare gains exclusive marketing rights in the EU and UK. The collaboration positions BioVaxys for potential entry into the US market with Procare's Papilocare™ product.
BioVaxys Technology Corp. (OTC: LMNGF) has entered a collaboration with Procare Health for the co-development and marketing of vaccines targeting ovarian cancer, cervical cancer, and HPV. The partnership includes a Phase I Clinical Study of BioVaxys' BVX-0918A vaccine in Spain, sharing costs and responsibilities. Procare Health gains exclusive rights to market BVX-0918A in the EU and UK. Additionally, BioVaxys has the right of first refusal to market Procare’s Papilocare™ in the US, a significant step towards revenue generation.
BioVaxys Technology Corp. (OTC: LMNGF) announced promising results for its Covid-19 vaccine candidate, BVX-0320, which showed a neutralizing antibody response against SARS-CoV-2 in a preclinical murine model study. Conducted in collaboration with The Ohio State University's Wexner School of Medicine, the study demonstrated that BVX-0320 stimulates production of neutralizing antibodies and activates T-cell responses. BioVaxys emphasizes the importance of T-cell memory for long-term immunity, although it has not claimed efficacy against SARS-CoV-2 at this time.